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Clinical testing of antiretroviral drugs as future 
prevention against vaginal and rectal transmission of HIV 
infection – a review of currently available results
The original purpose of vaginally applied microbicides was to 
slow down the HIV epidemic among the population until an 
effective vaccination was developed. Nowadays, antiretrovi-
rals applied in the form of gels or vaginal rings are considered 
most prominent in this field and are tested via vaginal or, rare-
ly, rectal applications in numerous clinical studies (9 different 
antiretroviral drugs in 33 clinical studies, especially in Africa). 
Only tenofovir (1 % gel) and dapivirine (25 mg in vaginal ring) 
progressed into the phase III clinical testing. Their efficiency 
depended on the user ś strict adherence to the application 
regimen (for tenofovir 54 %, for dapivirine 61 % in participants 
over 25 years of age). Despite this, they are expected to be im-
portant and effective tools of preventive medicine in the near 
future. This review summarizes the results obtained during 
long-term clinical testing (2005–2018) of antiretroviral drugs 
against vaginal and rectal transmission of HIV infection. 
Keywords: HIV prevention, microbicides, clinical trials, anti-
retro viral drugs
INTRODUCTION
The first case of HIV (human immunodeficiency virus)/AIDS (acquired immunodefi-
ciency syndrome) was reported in 1980 and the prevalence has been rising since then (1). 
Currently, the numbers associated with this infection are more than alarming. Since the 
epidemic, the estimated cumulative number of HIV infections in the world to date is 
around 76 million people, of which more than 35 million have died. In 2016, according to 
the World Health Organization (WHO), 36.7 million people lived with the HIV diagnosis 
worldwide. In the same year, 1.8 million new infections occurred with 1.0 million people 
dying from AIDS-related illnesses, compared to 1.9 million in 2005 and 1.5 million in 2010. 
This continuous decrease in deaths can be explained by the massive use of expensive an-
tiretroviral therapy. According to WHO, about 19.5 million patients were treated in 2016, 
which means that 53 % of infected patients were treated. This is a major improvement over 
2010 when approximately 23 % of infected people were treated (2).
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Microbicides are experimental products for the prevention of HIV sexual transmis-
sion, since none have been licensed yet. They are self-administered, vaginal or more re-
cently rectal preparations intended for women, homosexuals and transgendered individu-
als as a protection against HIV transmission. The main purpose of their development had 
been to slow down the HIV epidemic. The original idea was to shorten the time required 
for the development of an effective vaccine. Even though more than 35 years have passed 
since the HIV virus was first identified, no vaccine is available yet. Hundreds of HIV-1 
vaccine trials have been documented to date, but only six of those clinical trials included 
efficacy studies (3). For this reason, another form of effective prevention is extremely im-
portant because current prevention is based only on standard barrier protection during a 
sexual intercourse with a male or female condom. Especially in developing countries, cul-
tural, political or legal factors often affect the ability of women to protect themselves from 
HIV. As a consequence, many women and girls often do not have the power to refrain from 
sex, or to persuade their partners to use condoms. From this point of view, prompt avail-
ability of microbicide products is pressing. On the other hand, willingness of the sexually 
active population to use such products is a huge factor in solving this problem. 
Research of microbicides has proceeded for over twenty years (4). The funding to sup-
port this research has reached astronomical values, with cheaper microbicide candidates 
having completely failed, exhibiting no effectiveness. Only clinical trials of vaginal anti-
retroviral active pharmaceutical ingredients (APIs) have provided tangible evidence that 
this pathway may be beneficial. The aim of this review is to summarize the available in-
formation about clinical testing of antiretroviral APIs against vaginal and rectal transmis-
sion of HIV infection from 2005 to 2018.
DEFINITION AND CLASSIFICATION OF MICROBICIDES AND THEIR MECHANISM 
OF ACTION
Originally, the group of microbicides included substances from different pharmaco-
logical groups. Given that most of them were shown to be completely ineffective in clinical 
trials, the most promising APIs currently considered belong to the group of antivirals. The 
name “microbicides” was originally used for a group of APIs against different sexually 
transmitted diseases (mostly bacterial). Over time, the number of APIs, specifically against 
HIV, was gradually increasing among them. In view of this fact, this designation is not 
entirely appropriate. According to the current concept, a microbicide can be defined as a 
chemical agent used in various topical (vaginal, rectal) application regimes that kills, neu-
tralizes or blocks the HIV virus and other sexually transmitted pathogens, especially hu-
man papilloma virus (HPV), herpes simplex virus 2 (HSV-2) and others. Different dosage 
forms can be used for vaginal application, such as gels, creams, films, tablets or vaginal 
rings. As for rectal use, gels are considered to be the most preferable dosage form. The 
microbicide preparation is applied before and sometimes also after an intercourse, while 
the vaginal ring remains longer in the vaginal cavity. 
Microbicides were formerly divided into two generations. The first-generation micro-
bicides included non-specific and partially specific microbicides that were effective against 
a broader spectrum of sexually transmitted diseases, often with a spermicidal effect (5). 
The second-generation microbicides include specific microbicides that act only against 
HIV (6). Nowadays, this former division of microbicides into non-specific, partially spe-
299
J. Vysloužil et al.: Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV 
infection – a review of currently available results, Acta Pharm. 69 (2019) 297–319.
 
cific and specific can be considered as obsolete. It has been demonstrated in clinical testing 
that certain efficacy against HIV transmission is exhibited only by microbicides based on 
antivirals (Table I). However, for completeness we also provide information about clinical 
trials of the first-generation substances (Table II).
UNSUCCESSFUL MICROBICIDE CANDIDATES FOR VAGINAL USE
Microbicide clinical trials started with studies of non-specific and partially specific 
candidates. The first tested API was nonoxynol-9 from the surfactant family (Advantage 
24, Columbia Research Laboratories, Rockville Center, New York, USA). Clinical trials 
were conducted from 1992–2002 with negative results. This surfactant, commonly used 
Table I. List of antiretroviral candidates investigated as microbicides
Microbicide Classification (mechanism of action)
DS003 (BMS793) 
Entry inhibitor (It interferes with HIV infection by binding to protein 
gp120 and prevents CD4 from inducing structural changes in gp120 which 
drive the fusion protein gp41 to form six helix bundles and cause viral and 
cellular membranes to fuse) (7)
Emtricitabine
Nucleoside reverse transcriptase inhibitor (It is a prodrug that must be 
phosphorylated intracellularly into its active triphosphate form, emtricitabine 
5′-triphosphate, which is incorporated by reverse transcriptase into the 
elongating proviral DNA chain leading to termination of DNA synthesis) (8)
Maraviroc
CCR5 antagonist (It exhibits an ability to bind to the chemokine receptor 
CCR5 of CD4+ T-lymphocyte and blocks the binding to viral receptor  
gp120) (9)
MIV-150
Non-nucleoside inhibitor of HIV-1 reverse transcriptase (It is an allosteric 
inhibitor that indirectly interferes with the catalytic mechanism of the 
enzyme) (10)
MK-2048 HIV-1 integrase strand transfer inhibitor (It block integration of viral cDNA
 
into the host cell genome) (11)
Tenofovir Nucleotide reverse transcriptase inhibitor (It disrupts the synthesis of DNA chain, used to integrate into cell genetic material) (12)
Tenofovir disoproxil 
fumarate Nucleotide reverse transcriptase inhibitor (prodrug of tenofovir) (13)
TMC120 (dapivirine)
Non-nucleoside inhibitor of HIV-1 reverse transcriptase (It is an allosteric 
inhibitor that indirectly interferes with the catalytic mechanism of the 
enzyme) (14)
UC781
Non-nucleoside inhibitor of HIV-1 reverse transcriptase (It is an allosteric 
inhibitor that indirectly interferes with the catalytic mechanism of the 
enzyme) (15)
Vicriviroc CCR5 antagonist (It binds to the chemokine receptor CCR5 of CD4
+ 
T-lymphocyte and blocks the binding to viral receptor gp120 (16)
CCR5 – C-C chemokine receptor type 5, CD4 – transmembrane glycoprotein receptor for HIV-1, cDNA – comple-
mentary DNA, gp – glycoprotein
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also as a spermicide (24), was applied as a gel (25), sponge (26) or film (27). However, it did 
not exert effective protection against HIV infection and, moreover, it caused damage of the 
vaginal mucous membranes and/or vaginitis. It was therefore excluded as a potential mi-
crobicide (28). Another surfactant, Savvy® (C31G; N,N-dimethyldodecanamine oxide 2-(do-
decyldimethylazaniumyl)acetate) in gel form (C31G, Cellegy Pharmaceuticals Inc., 
Huntingdon Valley, Pennsylvania, USA), was shown to be a safe but yet ineffective form 
against HIV transmission (29). Phase III clinical testing took place in Nigeria and Ghana 
in 2004–2006.   
The failure of surfactants was followed by clinical trials with polymeric substances of 
low toxicity such as poly-anions and substances keeping the acidic vaginal pH at a normal 
level. Even in this group, however, no significant success was recorded. Phase III clinical 
testing of an anionic cellulose sulfate (Ushercell™, Polydex Pharmaceuticals, Bahamas, 
tested as a 6 % gel) conducted in India and Uganda was prematurely stopped because of 
the increased incidence of HIV infection compared to the placebo group. Anionic carrageenan 
(Carraguard®, FMC, USA), though non-irritable (5), showed no efficacy in the clinical study 
conducted in South Africa in 2004–2007 (30, 31). Similarly, no satisfactory results were 
Table II. List of non-specific and partially specific microbicide candidates
Group Microbicide Effect
Surfactants Nonoxynol-9, C31G, sodium lauryl sulfate
Disruption of the outer lipid membrane of 
viral particle, contraceptive effect, effect 




Polyacrylic acid, Carbopol® 
974P
Buffering effect maintaining vaginal pH 
around physiological value and prevents 




copolymers of d-galactose and 
3,6-anhydro-d-galactose; 
sulfonated and unsulfonated 
forms)
Electrostatic interaction between the 
negatively charged carrageenan surface 
and the positively charged surface of HIV 
– entry or fusion inhibitors with target 
immune cells (19, 20) 
Polynaphthalene sulfonate
Binding to HIV-1 gp120 and interference 
with virus attachment to and/or fusion 
with CD4+ T-lymphocytes (also interaction 
with CD4 and CXCR4 receptors) (21)
Cellulose sulfate
Binding the gp120 of HIV-1 envelope, 
inhibition of both CXCR4 and CCR5, 
inhibition of viral particle input or fusion 
with target immune cells (20, 22)
Dendrimer SPL7013 (highly 
branched, well-defined, 
three-dimensional structures 
with different surface groups)
Blocking HIV-1 envelope mediated 
cell-to-cell fusion, inhibition of viral entry 
with similar potency against CXCR4 and 
CCR5 (23)
CD4+ – transmembrane glycoprotein receptor for an HIV-1, CXCR4 chemokine receptor type 4, gp – glycoprotein
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obtained for polynaphthalene sulfonate (PRO 2000®, Endo Pharmaceuticals, Inc., USA) (32, 
33). With high expectations, the dendrimer SPL7013 (Vivagel®, incorporated in carbomer 
gel; Starpharma Holdings Limited, Australia) was tested (23). In phase I clinical testing 
(2004), it was well tolerated by women (34). A clinical study (2008–2009) revealed 70 % 
anti-HIV efficacy of vaginal fluid after the gel application (35). Unfortunately, though no 
other clinical study of Vivagel® as a microbicide has been performed yet, its therapeutic 
effect on vaginal inflammation was recently demonstrated (36). Buffer gel (a gel-based 
mucoadhesive preparation) (ReProtect LLC, USA) was tested for its ability to keep the 
vaginal pH acidic to support the vaginal mucosa natural defense (37). In a clinical trial, 
where it was tested together with PRO 2000®, its efficacy was not demonstrated (38).
ANTIVIRALS IN HIGHER PHASES OF CLINICAL TESTING
Today, antiretroviral (ARV) APIs are at the forefront of interest. The most prominent 
ones are certainly tenofovir (TFV) and dapivirine (DPV). Basic information about com-
pleted clinical trials on antivirals during the period 2005–2018 is summarized in Tables III, 
IV and V. 
Clinical testing of tenofovir vaginal preparations 
In 2007–2009, a clinical trial called CAPRISA 004 (Centre for the AIDS Programme of 
Research in South Africa), phase IIb clinical testing of the 1 % TFV hydrophilic gel took 
place as a double-blind, randomized, placebo-controlled clinical trial. The main aim of this 
clinical study was to investigate the safety and also the efficacy of this vaginal gel to pre-
vent HIV infection among 889 participants from the South Africa region. Women used the 
gel before and after sexual intercourse. The gel was very well tolerated, both by sexually 
active and abstinent women (39). The results of the study confirmed an overall 39 % effi-
cacy, even with the inclusion of women who had rarely forgotten the application of gel 
during the study. Under strict adherence to the regime, the inclusion of women who ap-
plied the gel correctly was efficacious up to a promising 54 % (40). The study also found that 
HIV transmission depended on TFV concentration in the cervico-vaginal fluid (CVF). At a 
concentration above 1000 ng mL–1, protection was demonstrated in 76 % of volunteers (41). 
Subsequently, in phase III, the clinical trial VOICE (Vaginal and oral interventions to 
control the epidemic) included more than five thousand women and was conducted in 
2009–2012. Daily use of a 1 % TFV gel was compared with oral tablets with TFV (Viread®; 
Gilead Sciences, Inc., USA) and the oral combination of TFV and emtricitabine (Truvada®; 
Gilead Sciences, Inc., USA) (42). In comparison with CAPRISA 004, this brought shocking 
results on the efficacy of the 1 % TFV gel. The preparation was proved to be completely 
ineffective without any positive result against HIV transmission. While the study partici-
pants reported 90 % adherence confidence in keeping the study protocol, their adherence 
determined on the basis of plasma concentration was only 22 %.
In other trials, phase III clinical testing FACTS 001 (Follow-on African consortium for 
tenofovir studies) verifying the efficacy of the 1 % TFV gel was run from 2011 to 2014 in 
South Africa. Among 2059 women, 123 cases of HIV infection were detected; 61 cases were 
found in the group using 1 % TFV gel (applied before and after intercourse) and 62 in the 
placebo group. It is clear from this result that no significant effect of the 1 % TFV gel was 
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confirmed (43, 44). According to a detailed analysis of the results, a lack of discipline in 
women using this gel, especially young, single individuals, living with their parents, was 
probably responsible for the lack of effectiveness. Low compliance of the participants in the 
study was probably caused by the application form (gel) and the complicated administra-
tion regimen. It was revealed that gel application before and after a sexual intercourse was 
too demanding, especially for young women. The recently completed follow-up post-trial 
access study with the 1 % TFV gel CAPRISA 008 (45) was focused on ensuring the adherence 
of participants with a coitus-related dosing regimen (exhibited through the mean number 
of returned used applicators per participant per month). The main approach was to inte-
grate TFV gel (CONRAD, Arlington, Virginia, USA) provision into family planning services. 
Women participating in the relatively successful clinical trial CAPRISA 004 were invited for 
CAPRISA 008. The process of negotiating gel use was determined in part by the quality of 
the relationship such as its duration, living situation, culturally-defined steps, etc. (46). 
However, according to the latest research, the reason for the TFV microbicide gel fail-
ure could also be seen in the composition of the vaginal microbiom of CAPRISA 004 par-
ticipants (47). The results revealed that TFV reduced the HIV incidence by 61 % in Lactoba-
cillus-dominant women but only 18 % in women with non-Lactobacillus bacteria. The 
detectible mucosal TFV concentration was lower in non-Lactobacillus women, yet negatively 
correlated with Gardnerella vaginalis and other anaerobic bacteria, which consequently de-
pleted TFV in the female body more rapidly (48). 
Clinical testing of dapivirine vaginal preparations   
Clinical trials with DPV as an anti-HIV vaginal microbicide agent started in 2005. Two 
prospective, randomized, double-blind, placebo-controlled phase I/II clinical studies 
(IPM003) were conducted at five research centers in Africa and Belgium in 2005–2006. A 
group of 112 women were tested for safety, tolerability and systemic absorption of DPV 
from the vaginal gel (0.02 %) after its administration twice a day for 42 days; a group of 28 
participants used placebo in the same regimen. A total of five serious adverse events 
occurred in these two studies, and none was assessed as related to the studied gel. The 
maximum observed mean concentration was 474 pg mL–1 on day 28. Two weeks after the 
final application of the gel, mean concentrations decreased to 5 pg mL–1 or less. Based on 
the results, daily use was recognized as a safe and well tolerated method with low systemic 
absorption in healthy women (49). 
Later in 2007–2008, the pharmacokinetics (PK) and safety study IPM005B (double-
blind, randomized, placebo-controlled) of two DPV vaginal gels was conducted in Belgium 
on 36 healthy women to assess plasma, vaginal fluid and vaginal tissue levels of DPV and 
PK of DPV when applying either gel 4750 (0.05 %, 2.5 g) or 4789 (0.05 % 2.5 g) (International 
Partnership for Microbicides, Bethlehem, Pennsylvania, USA) intravaginally for 11 days. 
This was done to assess the safety of these gels in comparison with the intravaginal 
hydroxyethyl cellulose (HEC) placebo gel. In conclusion, both gels were safe and well 
tolerated with low systemic absorption. The DPV concentration in vaginal fluids was more 
than 3 logs higher than plasma levels, which resulted in a significant reduction in viral 
load with oral DPV. Even though the DPV gel was successful in clinical testing, further 
investigation of its efficacy did not continue (50).
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On the other hand, the dosage form with long-term drug release, the vaginal ring 
(VR), appeared in the following years (51). The VR can be defined as a self-administered, 
flexible, torus-shaped, matrix or reservoir drug delivery device based on indifferent bio-
compatible polymers, such as silicones, polyethylene-vinyl acetate polymer, or polyure-
thanes intended for prolonged release of several weeks or months (52). 
IPM 015, a safety and acceptability I/II phase study of DPV vaginal ring (25 mg) (In-
ternational Partnership for Microbicides, Silver Spring, Maryland, USA) was run in 2010–
2011. The enrolled 280 women came from different places in Africa. Compared to the pla-
cebo VR, the DPV vaginal ring was generally perceived as safe and well-tolerated for up 
to 12 weeks of continuous use. Adverse events (pelvic abnormalities, vaginal discharge, 
intermenstrual bleeding) generally occurred with similar frequency for both DPV and 
placebo ring users. The majority of participants (60 %) in both ring groups reported that 
their male partners did not feel the ring. A further 22 % reported that their partners felt 
the ring during the intercourse, but that it was not a problem. Only a small number (1–3 
%) reported that her male partner felt the ring and that it might be, or definitely was, a 
problem for her to continue using it. Self-reported adherence to daily use of DPV VR was 
very high and the vaginal ring was acceptable to the majority of participants, who also 
reported that they would be willing to use it in the future if it was proven effective (53). 
The DPV vaginal ring (QPharma, Malmö, Sweden, under contract with the Interna-
tional Partnership for Microbicides) is currently being evaluated in phase III clinical test-
ing. A double-blind, randomized, placebo controlled clinical study ASPIRE (a study to 
prevent infection with a ring for extended use) was conducted in 2012–2015 with 2629 
women involved from different parts of Africa. Overall, the results of this trial confirmed 
27 % efficacy to prevent HIV infection. Significant dependence of efficacy on the age of 
participants was clearly demonstrated. For women under 25, only a 10 % result rate was 
shown while the efficacy for women older than 25 years was up to 61 % (54). A similar 
study (IPM 027) was conducted among 1959 healthy sexually active women aged from 18 
to 45 originating from seven communities in South Africa and Uganda. The incidence of 
HIV-1 infection had a 31 % lower result rate in the DPV group than in the placebo one. 
There was no significant difference in DPV VR efficacy in dependence on age. Among 
participants with a HIV-1 infection, non-nucleoside reverse-transcriptase inhibitor resis-
tance mutations were detected in 18.2 % of the participants in the DPV group and 16.1 % 
in the placebo group (55). 
Given the potential for interactions with co-administered vaginal products, PK as-
sessments were made during the co-use of the DPV vaginal ring and a commonly used 
antifungal API miconazole nitrate (MN) (1200 mg) in the form of vaginal capsules. The 
clinical trial IPM 028 was conducted in Belgium among 36 healthy women. Participants 
used the DPV VR so called Ring-004 (QPharma, Malmö, Sweden) for 28 days, alone or to-
gether with a single dose of MN. Concomitant use of the two products was safe and well 
tolerated. One product-related adverse event occurred (vulvovaginal candidiasis – in the 
arm of ring alone). A single vaginal dose of MN at the time of DPV vaginal ring insertion 
increased the systemic exposure of DPV by approximately 20 %, but decreased DPV CVF 
levels up to 14 days post ring insertion. CVF levels remained sufficient for HIV-1 inhibition 
in cervical tissue. Local and systemic miconazole exposure was increased after co-admin-
istration with DPV Ring-004 (1.4 to 6-fold higher). Concomitant use of Ring-004 with a 
single vaginal dose of MN altered the local and systemic levels of both drugs, but these 
changes were considered unlikely to affect adversely the efficacy of either drug (56). Later, 
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a similar clinical study (IPM 036) investigating the drug-drug interaction between Ring-
004 and a cream containing 1 % clotrimazole was already completed, but no scientific data 
are currently available (57).
The fate of the DPV ring continued in a clinical study known as MTN-023/IPM 030. It 
was designed to provide the kind of information about safety and tolerability of DPV VR 
that regulatory authorities would need to expand the approval of the ring to include its use 
also for girls under the age of 18 (58). The study was a multi-center, two-arm, randomized, 
double-blind, placebo-controlled phase IIa clinical trial. Objectives of the trial included the 
evaluation of acceptability and adherence to a VR when inserted once every 4 weeks for a 
24-week period with evaluation of local and systemic DPV exposure. The VR was found to 
be safe and acceptable by American adolescent girls. There were no differences in safety 
outcomes between the treatment arms (3:1 to a DPV or placebo ring). In the DPV group, 
drug levels indicated adherence in 87 % of plasma samples and 95 % of rings. Participants 
noted no discomfort due to the ring at 87 % of visits and “liking” the ring at 93 % of visits 
(59). This VR subsequently entered the phase I clinical testing (MTN-029/IPM 039) for 
breastfeeding women. The study was not blinded, focusing on the PK of the drug and the 
transfer of DPV into breast milk. Women included in the study had stopped breastfeeding 
their babies but could still produce breast milk, which was also analyzed. They were asked 
to leave the VR in place for 14 days. All participants had detectable DPV levels in plasma 
and milk with median peaks of 676 pg mL–1 and 327 pg mL–1, resp. Researchers estimated 
that an infant’s daily exposure to the drug would be very low (68.0 ng kg–1 per day) and 
without any substantial health risks for breastfed infants (60).
Similarly, like in the case of TFV gel, adherence measurement of the vaginal ring use 
within the clinical trial setting remains a challenge for the HIV prevention field. Direct 
post-use measurement of the rest drug assay could be used as a suitable approach towards 
understanding and assessing adherence (61).
The newest phase III/IIIb clinical studies are MTN-025 (HOPE) (62) and IPM 032 
(DREAM) (63) focusing on the safety of and adherence to the DPV (25 mg) Ring-004 
inserted at monthly intervals. These open-label trials included participants from the South 
Africa region. Although the trial is not yet completed, preliminary results presented at the 
Conference on Retroviruses and Opportunistic Infections in Boston (2018) indicated a 
similar safety profile of DVR to that observed in phase III. Both studies found high adher-
ence (~90 % of returned rings had residual levels of DPV consistent with at least some use). 
HIV incidence in both studies was much lower than expected – 1.9 % per year for HOPE 
and 1.8 % per year for DREAM; these are much lower than the placebo incidence in ASPIRE 
(> 4 % per year). The results were remarkably similar and showed that the HIV incidence 
observed in the open-label extension studies was about 54 % lower than expected. More 
analyses of the studies will be coming in the next couple of years (64).
CURRENT CHALLENGES
The most suitable dosage form for microbicides
For women, the future use of microbicide preparations could be certainly seen in the 
form of a vaginal ring. When compared to gel, the vaginal ring ensures satisfactory 
compliance with the dosing regimen (65). Final clarification of this issue could be found in 
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the recently completed clinical trial QUATRO conducted in South Africa and Zimbabwe 
and sponsored by CONRAD. The purpose of the QUATRO study was to assess the users’ 
experience, acceptability, preferences and the effect on sexual behaviour of four different 
vaginal delivery forms: the rapidly disintegrating vaginal insert, vaginal ring, film and 
gel. The results are expected in the near future (66, 67). Although gels and vaginal rings 
are currently considered as the most suitable application forms, the research focuses also 
on other dosage forms. The proof is the phase I clinical testing FAME 02 and FAME 02B of 
a novel DPV vaginal film (composed of polyvinyl alcohol). The FAME 02 study was fo-
cused on its safety, acceptability, PK and pharmacodynamics (PD). Participants were ran-
domized to a daily DPV (0.05 %) (Microbicide Trials Network, Silver Spring, Maryland, 
USA) or placebo gel (CONRAD, Arlington, Virginia, USA), or DPV (1.25 mg) or placebo film 
for seven days. Women rated the film more comfortable with less leakage but found it more 
difficult to insert than gel. Both film and gel delivered DPV at concentrations sufficient to 
block HIV ex vivo (68). In FAME 02B, participants were randomized to receive either DPV 
vaginal gel or DPV vaginal film of the same drug dose (1.25 mg). Occurrence of mild to 
moderate adverse events was similar among the products. The DPV film and gel per-
formed similarly in terms of tolerability, pharmacokinetics, and reduction of cervical tis-
sue infectivity after ex vivo HIV challenge 5 hours post dose (69).
 It can also be noted that some recent clinical trials investigated microbicide drugs 
formulated into vaginal tablets, as it will be mentioned later. On the other hand, gels and 
enemas are the most suitable dosage forms for rectal administration so far (70).
Antiretroviral APIs firstly used for vaginal administration 
At present, different antiretroviral drugs, which have not yet been used for this pur-
pose, appear in the first phases of clinical testing (Table V). Some information about these 
active agents can be found in the literature and official internet sources.
 Although the antiretroviral effect of thiocarboxanilide UC-781 has been tested since 
2005, it still remains only in phase I clinical testing. The first clinical study NCT00132444 
was focused on the safety and acceptability of 0.1 % UC-781 and 0.25 % UC-781 Carbopol® 
gel (CONRAD, Arlington, Virginia, USA) administered vaginally twice a day for 14 days 
in two intermenstrual weeks (71). Even many years after completion, the results of this 
clinical study are not available. Similarly, the clinical trial NCT00441909 was conducted 
to reveal local and systemic safety for a one-time dosage of UC-781 0.1 % gel for vaginal 
use for different durations of exposure (2, 4, 8 h) in HIV uninfected women (72). Only 2 
women in the drug-loaded gel group had detectable systemic UC781 levels, however be-
low the limits of quantification. The most frequently reported adverse events were geni-
tourinary with a similar distribution in the placebo and UC-781 gel arms. Vaginal secre-
tion was collected to test antiviral activity against HIV and assess the amount of 
microbicide remaining in the vagina. The initial CVF drug concentration was signifi-
cantly higher than the known IC50 for HIV-1. Active drug levels were detected in CVF and 
vaginal swab specimens on days 1–2 at concentrations supporting daily dosing (73). Lo-
cated in Thailand, the second parallel clinical study NCT00446979 controlled by placebo 
(HEC) with the twice a day application regimen for 14 days was targeted at safety and 
acceptability of the UC-781 gel only for women and their male partners (74). Partial results 
of this clinical study were published by Haaland et al. (75). Only a group of 25 Thai 
women was included in testing of whether UC781 retained anti-infective activity follow-
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ing exposure to the female genital tract. Ex vivo analysis of the UC781 levels and anti-
HIV-1 activity in the soluble supernatant fraction (CVF-s) and pelletable fraction (CVF-p) 
of CVF were determined. As UC781 is highly hydrophobic, there were significantly higher 
levels of UC781 in the CVF-p samples than in the CVF-s samples for the UC781 gel arms. 
Especially in the 0.25 % UC781 gel arms, infection with ≥ 4 log10 50 % tissue culture infective 
dose of HIV-1 was efficiently blocked. This study also confirmed a 93 % self-reported 
adherence to gel use. The numbers and types of adverse events were similar in the study 
arms. Despite satisfactory results in phase I clinical testing, the UC 781 gel did not progress 
to other phases.  
In the phase I clinical testing NCT02006264, the polyurethane vaginal ring with a 
content of tenofovir disoproxil fumarate (TDF) was used continuously for 14 consecutive 
days in 30 women to investigate the safety and PK in a randomized single-blinded placebo 
VR controlled regimen. Drug concentrations were measured in CVF, cervical tissue, plasma 
and dried blood spots. During the study, there were eight product-related mild adverse 
events. CVF collected from the cervix one week and two weeks after the TDF VR insertion 
provided significant protection against ex vivo HIV challenge. The TDF VR was recognized 
as safe, well tolerated, and resulted in mucosal TFV concentrations that exceeded those 
associated with HIV protection (76). 
For the first time administered vaginally, PC-1005 (combination of MIV-150 and zinc 
acetate in carrageenan gel) was tested in the phase I clinical trial NCT02033109 evaluating 
its safety, PK and acceptability (77). In the end, only 20 participants were included into the 
published data. Used vaginally for 14 days, PC-1005 (Center for Biomedical Research, New 
York, USA) was well tolerated by the participants. One third of participants reported they 
liked the gel; two thirds recommended reducing its volume. Low systemic levels of MIV-
150 were observed and plasma zinc levels were unchanged. The post-dose CVF samples 
showed anti-HIV and anti-human papilloma virus activity (78). 
The new, promising antiretroviral drug DS003 was tested in the form of vaginal tab-
lets in a double-blinded phase I clinical trial IPM 042 to determine their safety and toler-
ability. It was the first time that DS003 was being studied in humans. The trial was sup-
posed to be completed in the second half of 2016 (79). The results are still unavailable.
Combination of more antiretroviral drugs for vaginal application 
The new approach in this field is a combination of more antiviral drugs in one prepara-
tion, which is considered to be a more effective approach with lower likelihood of resistance. 
Phase I clinical testing (MTN-013/IPM 026) of VRs containing 25 mg of DPV and 100 mg 
of maraviroc (MVC) and their combination (DPV/MVC ring), resp., has been completed 
(80, 83). The randomized double-blinded study was designed to determine the safety, PK 
and PD. It can be concluded that all the tested rings were safe and well tolerated without 
adverse effects for a period of 28 days. DPV/MVC rings had higher peak concentrations 
(Cmax) and overall drug exposure (AUC) in CVF compared to the rings with individual 
drugs. The early peak and significant gradual fall in concentration of MVC indicated an 
inefficient drug delivery profile that resulted in early drug exposure excess (toxicity risk) 
and lower concentrations later (lack of efficacy risk). In the DPV preparation without 
MVC, a concentration-dependent inhibition of HIV-1 in cervical tissue was demonstrated. 
DPV concentrations in CVF were 100,000 times higher than plasma concentrations. MVC 
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concentrations were detectable only in CVF; however, the plasma levels were mostly beyond 
detectable limits, therefore further study of MVC release from VR is needed.
A combination of antiretroviral drugs TFV and emtricitabine (FTC) in the form of 
vaginal tablets was very successful in a preclinical study (81). A phase I clinical safety/PK 
trial of these tablet formulations was currently completed (NC01694407). In this first-in-
women study, the individual dose of TFV and FTC was 40 mg each. Unfortunately, the 
results are still expected (82).
Another clinical trial, MTN-027, evaluated the safety and PK of vicriviroc (VCV), in-
tegrase inhibitor MK-2048 and their combination (84, 85). In all cases, drugs were incorpo-
rated in the vaginal ring. Drug concentrations were quantified in the plasma, vaginal fluid, 
cervical tissue, and rectal fluid. Cervical tissue was utilized for the ex vivo HIV inhibition 
analysis. VCV and/or MK-2048 containing VRs were safe and acceptable. Most women (77 
%) fully adhered to 28 days of continuous VR use and found the VR acceptable. Both VCV 
and MK-2048 were quantifiable in all the matrixes tested with peak drug concentrations 
similar for both single and combination drug VRs. Tissue-associated VCV and/or MK-2048 
did not correlate with the inhibition of HIV infection. Therefore, a new investigation of 
drug dosing in VRs is needed. 
In the early phase I clinical study NCT02431273 (open-label safety, acceptability and 
pharmacokinetic study), the single pod-vaginal ring with TDF, dual vaginal ring contain-
ing drugs TDF/FTC and triple vaginal ring containing TDF/FTC/MVC for HIV prophy-
laxis were studied for 7 days (86, 87). Reported acceptability was high for all the three 
products. There were no serious adverse events during the study. No epithelial disruption/
thinning was seen by colposcopy, and no systematic vaginal microbiome changes were 
observed. Tissue concentrations of the drugs used exceeded the theoretical target concen-
trations for vaginal HIV prevention. In this study, a rectal drug exposure was also inves-
tigated. It can be concluded from the results that concentrations of FTC and MVC in the 
obtained rectal fluids exceeded the levels associated with in vitro efficacy in HIV inhibi-
tion. MVC appeared to reduce the distribution of TDV and FTC into the rectal lumen. 
Nevertheless, this strategy seems to be useful for dual-compartment protection.
Combination of antiretroviral drug with other APIs for vaginal application 
The future expected output is likely to be a combination of microbicides with other 
drugs such as agents protecting from other sexually transmitted pathogens (18) or contra-
ceptive drugs known as MultiPurpose Technologies developed by CONRAD (88). Pre-
clinical studies with a multifunctional VR containing TFV and levonorgestrel (LNG) indi-
cated that the VR is capable of sustained release of both drugs for 90 days (89). The TFV/
LNG VR is the first multipurpose prevention technology designed to reduce HIV, herpes 
infections and unplanned pregnancies. The phase I clinical study named CONRAD 128 
assessed the safety, acceptability, and APIs´ PK/PD (90). Participants were using VR for 
approximately 15 days. TFV/LNG VRs (TFV – 10 mg per day; LNG – 20 µg per day) were 
safe with no significant colposcopic, mucosal, immune or microbiota changes and were 
acceptable to women. Estimated in vivo, TFV and LNG release rates were within expected 
ranges. CVF of women completely inhibited HIV infection in vitro, the majority (95 %) were 
anovulatory or had abnormal cervical mucus sperm penetration. TFV/LNG rings are ready 
for expanded 90 day clinical testing (NCT03279120, completed 12/2018).
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Similarly, the three-month VR to protect women against HIV and unintended preg-
nancy was tested in a MTN-030/IPM 041 study at two different locations in the USA (91). It 
is the first in-human study of VR containing a combination of DPV (200 mg) and LNG (320 
mg). This clinical trial is completed but the results have not been published yet.
Male and female rectal microbicide gel 
The future of microbicides can also be seen in the development of a male and female 
rectal microbicide gel. The closest to clinical practice is a rectal preparation based on re-
duced glycerol content and 1 % TFV (CONRAD, Arlington, Virginia, USA). It is currently 
in the recently completed phase II clinical trial MTN-017. Its safety, drug absorption and 
tolerance after rectal administration were monitored. The study was attended by 195 men 
from the USA, Africa, Peru and Taiwan in 2013-2015 (92, 93). Adherence and product use 
likelihood were higher for the intermittent gel regimen (before and after anal intercourse) 
than for the daily gel use also due to the occurrence of diarrhea as an adverse event. The 
adherence of participants with intermittent gel regimens was 93 %, whereas adherence 
with the daily rectal regimen was only 83 %. 
The phase I clinical trial NCT00408538 investigated the UC-781 microbicide gel (0.1 % 
and 0.25 %; CONRAD, Arlington, Virginia, USA), which was applied rectally in partici-
pants of both sexes as a randomized, blinded, placebo-controlled safety and acceptability 
study (94). After using the UC-781 gel rectally for seven consecutive days, the participants’ 
feedback suggested that the UC-781 gel formulation was highly acceptable and comparable 
to a placebo gel. Rectal exposure to both concentrations of UC781 was safe with no sig-
nificant adverse events, no detected plasma drug levels and no significant mucosal changes. 
Ex vivo biopsy infections demonstrated marked suppression of HIV infectibility (more 
evident for 0.25 % concentration). 
The antiretroviral drug MVC was examined in the phase I clinical trial NCT02346084 
where a 1 % gel was tested in adult participants of both sexes (95). This trial was a random-
ized, open label, crossover safety and PK study of oral MVC tablets and 1 % MVC gel ad-
ministered rectally and vaginally in HIV-1 seronegative adults. The purpose of the study 
was to evaluate the safety, acceptability and the PK/PD profile of MVC gel following rectal 
and vaginal administration in comparison with oral MVC exposure. However, the results 
are still unavailable.
CONCLUSIONS
In the above mentioned clinical trials, a total of almost 20,000 participants were recru-
ited. Male participants were represented by only less than 1.5 %. Obviously, investigation 
of microbicides is currently focused on solving the problem of HIV transmission via vaginal 
route in the female population. Hydrophilic gels and VRs are most frequently selected as 
application forms. A recent clinical trial using films and vaginal tablets can be found. From 
the tested substances, only the most prominent tenofovir and dapivirine progressed into 
phase III clinical testing, other ARVs were investigated meanwhile in phase I. ARVs and 
generally exhibited safety and good tolerability comparable with the control group using 
placebo. The HIV inhibition activity in vaginal fluid ex vivo was recognized as satisfactory 
in many cases. The real efficacy of microbicide preparations was tested on 1 % TFV and 
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DPV VR with 25 mg of API. The efficacy of TFV gel in CAPRISA 004 exhibited a maximum 
value of 39 % against HIV transmission. On the other hand, the same gel completely failed 
in VOICE, FACT001. Thus, its efficacy is considered as fluctuating and strictly dependent 
on the user ś compliance with the application regimen (efficacy 54 % under strict patient 
adherence). Nevertheless, the 1 % TFV gel was integrated into family planning services in 
the post-trial access study CAPRISA 008. The other successful candidate, DPV incorpo-
rated into the ring, exhibited 27 % efficacy with an age-related dependency (61 % over 25 
years) in ASPIRE. The same VR was also relatively successful in IPM 027 with 31 % efficacy 
without age dependency. In the newest clinical trials HOPE and DREAM, preliminary 
results have shown as high as 54 % efficacy. At present, there is not enough evidence to 
conclusively recommend topical microbicides for HIV prevention. Further studies are 
needed to confirm the clearly beneficial effects of microbicide preparations with a focus on 
participant adherence. Only this can open the way to rapid regulatory approval and their 
maximal spread in the sexually active population.  
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